AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17303495
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 600 microg before D&E
Trial: 11796079
Drug: 8 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 sessions of group music therapy
Trial: 11796079
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no group music therapy)
Trial: 9401647
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose loading
Trial: 8017669
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with hyperbaric bupivacaine 0.5% (0.08 mg.cm‐1 of height)
Trial: 8017669
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia with a bolus dose of 0.5% plain bupivacaine followed by continuous infusion
Trial: 27570089
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg oral daily
Trial: 22104960
Drug: 80 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 kVp with MC‐CM (70 mL of 300 mgI/mL)
Trial: 22104960
Drug: 120 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 kVp with HC‐CM (70 mL of 370 mg iodine/mL)
Trial: 18457338
Drug: Monthly maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly maintenance Interpersonal Psychotherapy (IPT)
Trial: 10491544
Drug: Multiple-agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-agent chemotherapy and irradiation to the primary tumor volume
Trial: 10491544
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone injections
Trial: 8946439
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg and placebo (Group I, n = 13)
Trial: 8946439
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg plus dexfenfluramine 15 mg at night (Group II, n = 20)
Trial: 1934527
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of GRF 1‐29 (0.3 micrograms/kg/h)
Trial: 1934527
Drug: Clonidine pretreatment
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine pretreatment with GRF infusion
Trial: 6285533
Drug: Standard immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppressive therapy (antilymphoblast globulin, prednisone, and azathioprine)
Trial: 22327574
Drug: Compound control
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound control (‐ve S. Enteritidis, +ve 0.75% TC or 1% EG)
Trial: 22327574
Drug: Low-dose treatment
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose treatment (+ve S. Enteritidis, +ve 0.5% TC, or 0.75% EG)
Trial: 22327574
Drug: High-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose treatment (+ve S. Enteritidis, +ve 0.75% TC, or 1% EG)
Trial: 10673878
Drug: Tropisetron 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 0.1 mg kg‐1 to a maximum of 5 mg
Trial: 1918581
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 or 120 mg)
Trial: 7249345
Drug: one puff
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one puff in each nostril four times daily
Trial: 7249345
Drug: two puffs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two puffs in each nostril twice daily
Trial: 25019571
Drug: Brivanib 800
RxNorm normalized name: Brivanib
DrugBank: Brivanib (DB11958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib 800 mg orally every day until disease progression or prohibitive toxicity
Trial: 22110164
Drug: Both timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both timolol formulations
Trial: 17537764
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg weekly azithromycin
Trial: 17537764
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg daily azithromycin (in patients aged <18 yrs)
Trial: 17537764
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg weekly azithromycin (in children)
Trial: 11684377
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone (P) 200 mg/day
Trial: 8187108
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (NTG) - acute administration (2 days)
Trial: 8187108
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (NTG) - continuous administration (24 days)
Trial: 8187108
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (NTG) - intermittent administration (24 days)
Trial: 27736248
Drug: Nitrate supplementation
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate supplementation (NIT) - 70 mL of beetroot juice containing 4 mmol NO3‐ for 8 days
Trial: 21765964
Drug: Mass treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass treatment with anti-filarial drugs (4 annual administrations)
Trial: 21765964
Drug: Mass treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass treatment with anti-filarial drugs in communities with high pre-treatment transmission (224-742 infective bites/person/year)
Trial: 21765964
Drug: Mass treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass treatment with anti-filarial drugs in communities with moderate pre-treatment transmission (24-167 infective bites/person/year)
Trial: 19478342
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement provided in the morning and evening (n = 13)
Trial: 19478342
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement provided immediately before and immediately after workouts (n = 13)
Trial: 19478342
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 7) with no protein or other nutritional supplement
Trial: 12114886
Drug: Duloxetine 20
RxNorm normalized name: duloxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 20 mg/day
Trial: 11282251
Drug: Clomipramine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 100 mg/day
Trial: 9198080
Drug: Liquid non‐caloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid non‐caloric meal (5 mL water kg‐1)
Trial: 4042306
Drug: naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone (10 mg iv followed by a continuous infusion of 10 mg/hr)
Trial: 25636293
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control with oral hygiene instruction
Trial: 18528294
Drug: Autologous tumor
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor lysate-pulsed dendritic cell (DC) vaccine administered every other week for 3 doses
Trial: 18528294
Drug: Autologous tumor
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor lysate-pulsed DC vaccine followed by low-dose IL-2
Trial: 18528294
Drug: Autologous tumor
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor lysate-pulsed DC vaccine followed by high-dose IL-2
Trial: 10690134
Drug: Rapacuronium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapacuronium 1.5 mg kg‐1 with three incremental doses of 0.5 mg kg‐1
Trial: 10690134
Drug: Neostigmine vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine vs Edrophonium after three incremental doses of rapacuronium
Trial: 3080114
Drug: Recombinant hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hepatitis B vaccine derived from yeast
Trial: 3080114
Drug: Plasma derived
RxNorm normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma derived hepatitis B vaccine
Trial: 30359369
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of social and physical stress
Trial: 19761115
Drug: Spoon-needle cluster
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spoon-needle cluster (SNO) treatment
Trial: 19761115
Drug: Filiform-needle cluster
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filiform-needle cluster (FNC) treatment
Trial: 17174593
Drug: Control 1
RxNorm normalized name: Sebrx Acne Control 1 % Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control 1 (buccal smears prepared 1 week before the study)
Trial: 17174593
Drug: Control 2
RxNorm normalized name: Appetite Control 200mcg-500mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control 2 (buccal smears at the start of the study before first exposure)
Trial: 12241627
Drug: Clobetasone butyrate
RxNorm normalized name: clobetasone butyrate
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Clobetasone butyrate (CB) 0.05% cream
Trial: 14522623
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) 1% cream
Trial: 9273824
Drug: Control (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (other antihypertensive agents)
Trial: 3578745
Drug: Balanced solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced solution of electrolytes and trace metals (Inzolen) with aspartate as the anion (group C)
Trial: 27159758
Drug: Uterosacral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterosacral suspension
Trial: 27159758
Drug: Sacrospinous suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacrospinous suspension
Trial: 24477778
Drug: Evolocumab 140
RxNorm normalized name: evolocumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 140 mg every 2 weeks or 420 mg every month
Trial: 18427501
Drug: Sertraline (zofort)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (zofort) - selective serotonin reuptake inhibitor
Trial: 16161725
Drug: Voucher-based contingency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voucher-based contingency management for substance abuse treatment (criminal justice involved)
Trial: 16161725
Drug: Voucher-based contingency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voucher-based contingency management for substance abuse treatment (non-criminal justice involved)
Trial: 11252342
Drug: Ceftazidime 6
RxNorm normalized name: ceftazidime 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 6 g/day by continuous infusion
Trial: 11252342
Drug: Ceftazidime bolus
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime bolus dosing (2 g 8 hourly)
Trial: 1835276
Drug: Aspirin (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (a nonspecific inhibitor of thromboxane synthesis)
Trial: 1835276
Drug: Sulotroban (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulotroban (a specific thromboxane receptor antagonist)
Trial: 31521942
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus VCAT‐J
Trial: 26955982
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (TAU)
Trial: 19129355
Drug: Deep transthecal
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep transthecal injection
Trial: 19129355
Drug: Traditional transthecal
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional transthecal injection
Trial: 15218710
Drug: Colgate Simply
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate Simply White Clear Whitening Gel, three times daily, 30-second air-drying and 30 minutes without eating/drinking
Trial: 15218710
Drug: Colgate Simply
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate Simply White Clear Whitening Gel, four times daily, 30-second air-drying and 30 minutes without eating/drinking
Trial: 15218710
Drug: Colgate Simply
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate Simply White Clear Whitening Gel, twice-daily, no air-drying, and 15 minutes without eating/drinking
Trial: 9797080
Drug: G‐CSF 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 5 microg/kg per day subcutaneously starting 2 days after S‐HAM treatment
Trial: 2676877
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (PPA) 37.5 mg immediate release
Trial: 371318
Drug: 24 hours
RxNorm normalized name: PATCH, TRANSDERMAL 24 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hours of preoperative antibiotic bowel preparation (gentamicin + vancomycin + mycostatin)
Trial: 371318
Drug: 60 hours
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 hours of preoperative antibiotic bowel preparation (gentamicin + vancomycin + mycostatin)
Trial: 27859427
Drug: Citrate HDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate HDF (heparin free)
Trial: 27859427
Drug: Acetate HDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate HDF (routine dose of heparin)
Trial: 26383152
Drug: SB742457 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB742457 (3 mg/d)
Trial: 26383152
Drug: SB742457 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB742457 (15 mg/d)
Trial: 26383152
Drug: SB742457 (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB742457 (35 mg/d)
Trial: 26383152
Drug: SB742457 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB742457 (3, 15, and 35 mg/d)
Trial: 24136111
Drug: 8 h
RxNorm normalized name: Tylenol 8 Hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 h sitting interrupted with hourly, 8-min moderate-intensity cycling exercise bouts
Trial: 16248986
Drug: Aprepitant 160
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 160 mg
Trial: 13679549
Drug: Combined diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined diltiazem and aspirin/ticlopidine therapy
Trial: 13679549
Drug: Aspirin/ticlopidine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin/ticlopidine therapy alone
Trial: 1420752
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg b.d. plus Pirenzepine 50 mg b.d.
Trial: 1420752
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg b.d. plus Placebo (Control)
Trial: 22649265
Drug: 140 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 g/d of lipid-based nutrient supplements (LNS)
Trial: 22649265
Drug: No lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-based nutrient supplements (LNS)
Trial: 15551388
Drug: Valerian 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian 300 mg
Trial: 15551388
Drug: Valerian 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian 600 mg
Trial: 11431240
Drug: Intramuscular olanzapine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular olanzapine, 10 mg
Trial: 11431240
Drug: Intramuscular haloperidol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol, 7.5 mg
Trial: 7884790
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg to 15 mg once daily or 2.5 mg to 10 mg twice daily)
Trial: 7884790
Drug: Isradipine with
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine with concomitant HCTZ (12.5 mg to 50 mg once daily)
Trial: 30156056
Drug: Metformin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,000 mg, twice daily)
Trial: 30156056
Drug: Alogliptin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (25 mg, once daily)
Trial: 30268189
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (surgical method L)
Trial: 24200700
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L
Trial: 27919638
Drug: Ezetimibe 10mg
RxNorm normalized name: EZETIMIBE 10MG TAB
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe 10mg + Atorvastatin 80mg
Trial: 27919638
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Atorvastatin 80mg
Trial: 26240491
Drug: Restriction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restriction of suspected foods and/or administration of ketotifen in the pEGE group (n=9)
Trial: 17882913
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of cetirizine once per day
Trial: 17882913
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of zafirlukast once per day
Trial: 17882913
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of cafirlukast twice per day
Trial: 17882913
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 20 mg of zafirlukast and 10 mg of cetirizine once per day
Trial: 17882913
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 20 mg of zafirlukast twice per day and 10 mg cetirizine once per day
Trial: 17882913
Drug: Low-dose anti-LT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose anti-LT
Trial: 17882913
Drug: Antihistamine alone
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine alone
Trial: 17882913
Drug: High-dose anti-LT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose anti-LT or combination of low-dose anti-LT and antihistamine
Trial: 15215154
Drug: High-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intramuscular corticosteroids (triamcinolone)
Trial: 11577957
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + AUG (amoxicillin/clavulanic acid 500 mg tid)
Trial: 11577957
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + AUG (amoxicillin/clavulanic acid)
Trial: 2600826
Drug: Nicotine polacrilex
RxNorm normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine polacrilex gum (2 or 4 mg)
Trial: 2600826
Drug: Nicotine polacrilex
RxNorm normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine polacrilex (4 mg)
Trial: 28284926
Drug: Dextrose infusion
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose infusion (0.9% saline control)
Trial: 28284926
Drug: Acetylcholine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine infusion (both arms)
Trial: 28284926
Drug: Dextrose infusion
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose infusion (after reperfusion)